Wells Fargo & Company Enveric Biosciences, Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$8.8 - $16.2 $1,302 - $2,397	148 Added 15.23%	1,120 $0
Q1 2022 May 16, 2022	BUY	$12.5 - $52.0 $850 - $3,536	68 Added 7.52%	972 $0
Q3 2021 Nov 15, 2021	SELL	$80.5 - $175.0 $385,756 - $838,600	-4,792 Reduced 84.13%	904 $2,000
Q2 2021 Aug 16, 2021	BUY	$95.0 - $156.5 $457,235 - $753,234	4,813 Added 545.07%	5,696 $14,000
Q1 2021 May 13, 2021	BUY	$131.5 - $245.0 $114,405 - $213,150	870 Added 6692.31%	883 $2,000
Q4 2020 Feb 09, 2021	BUY	$74.0 - $740.0 $962 - $9,620	13 New	13 $0

Ticker ENVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,078,270
Market Cap $686K
Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.